Is the prescription effective The growth rate of the retail

On June 4, the first municipal electronic prescription information sharing service platform in Shanxi Province was officially launched, led by the Health Committee of Jincheng City, Shanxi Province. The platform will cover 22 secondary and above medical institutions in the city. Through the his system of the above medical institutions, the city's unified standard prescription database will be established.

in fact, similar models have been launched in many places in recent years. The launch of regional prescription information sharing platform has accelerated the realization of "prescription outflow". According to the data of Minet, the proportion of prescription drugs sold by urban retail pharmacies in 2019 will reach 51.0%, more than half for the first time. Among them, the highest annual growth rate is the chemical drugs of anti-tumor and immunomodulators, reaching 85.7%.

Internet plus Internet novel coronavirus pneumonia has dominated local

Since its issuance on the promotion of Internet plus medical health, the state and relevant ministries and commissions have issued several documents, involving access, payment, supervision and many other aspects, and the new crown pneumonia epidemic has accelerated the policy of "non-contact".

policy benefits attract many enterprises layout, such as the health of Ali, which announced the 2020 fiscal year results a few days ago, in April this year, combined with Alipay, in Ji'nan, Shandong took the lead in innovating the pilot's first internet medical mode based on electronic medical insurance vouchers, including "medical insurance electronic voucher application + online referral + online prescription transfer + online medical insurance payment + drugs". Including "home delivery", online medical insurance covering from consultation to drug purchaseOne stop service.

However, analysts also pointed out that the prescription information sharing platform led by the local health department, such as Jincheng, Shanxi Province, opens the port for the government's regulatory departments, so as to supervise the circulation of prescriptions in real time and in the whole process. Therefore, it is easier to obtain the qualification of Online payment and reimbursement of medical insurance, and finally realize the connection with the existing services, becoming a one-stop closed-loop drug purchase .

from the perspective of the whole chain of medical circulation, the greater significance of prescription information sharing platform is to connect the fragmented information systems between different levels of medical institutions, and solve the problem of online prescription circulation and sharing between hospitals and pharmacies. A hospital official who has launched the extension service disclosed that because the extension platform is not limited by the drug types of medical institutions, it can make prescriptions according to the specific conditions of patients through the platform, which enriches the doctor's diagnosis and treatment programs and benefits patients more.

antitumor drug retail terminal

rapid increase from the "Internet plus medical insurance" development trend, the current medical insurance payment is mainly involved in chronic diseases and common diseases, re visit treatment fees and related prescription fees. In fact, as major diseases such as cancer gradually show a trend of chronic disease, the number of patients who benefit from it is gradually expanding, and drugs for common diseases, chronic diseases, major diseases and other long-term use are also flowing out of hospital.

according to the data of MI Nei network, chemical drugs accounted for 54.5% of the drug sales scale of China's urban physical pharmacies (including cities at prefecture level and above) in 2019, an increase of 3.2 percentage points compared with 2018. fromIn terms of drug types, prescription drugs successfully accounted for half of the country, with a market share of 51.0%, an increase of 2.7 percentage points compared with 2018. Non prescription drugs accounted for 39.8%, and double span drugs accounted for 9.2%.

according to the analysis, this is closely related to the sales of new anti-tumor drugs approved in recent two years through out of hospital channels such as DTP pharmacy. A similar situation can be seen from the annual growth rate of each sub category. According to the data of mienei.com, the highest annual growth rate of chemical drugs in urban entity pharmacies in 2019 is anti-tumor and immunomodulators, accounting for 85.7%; coincidentally, the highest annual growth rate of Chinese patent medicines is also cancer drugs, accounting for 31.0%.

specifically, in 2019, the growth rate of terminal sales of retail pharmacies in China's cities will exceed 500%, and six of them will be antineoplastic drugs.

over 100 million chemical drug brands (unit: 10000 yuan) with a sales growth rate of more than 500% in urban retail drugstores in 2019

Among them, the most powerful is the Roche aletinib hydrochloride capsule, which was included in the priority review in March 2018 and approved to enter the Chinese market in August of the same year. It is used to treat locally advanced or metastatic non-small cell lung cancer with positive ALK. According to the data of minenet, at the terminals of public medical institutions in China, the sales volume of Roche's aletinib hydrochloride capsules was 8.88 million yuan in 2018, and soared to 139 million yuan in 2019, with a growth rate of 1461.71%;In China's urban retail drugstore terminals, the sales volume of the product was 890000 yuan in 2018 and soared to 211 million yuan in 2019, with a growth rate of 23608.99%. Considering that aletinib hydrochloride capsule has been successfully included in the national medical insurance negotiation catalogue of 2019, it is expected that the sales of the product in China's public medical institutions will continue to rise in 2020.

the paclitaxel for injection (albumin binding type) of Hengrui medicine, which was approved for production in 2018, was regarded as over evaluated. According to the pattern data of retail pharmacies in China's cities on minet.com, the sales of this drug increased by 6434.85% in 2019, exceeding 900 million yuan. Xinji, the original research enterprise of the product, was announced by the State Food and Drug Administration in March this year. It was found that some key production facilities did not meet the basic requirements of China's drug production quality management during the on-site inspection of overseas production, and the aseptic safeguard measures were not in place in the production process. Therefore, the import, sales and use of the product were suspended in accordance with the law. It is expected that domestic brands will continue to share market space.

the growth rate of olaparide of AstraZeneca was the third. In January 2018, the drug was included in the priority review on the grounds of "obvious treatment advantages compared with existing treatment methods"; then it was approved for maintenance treatment of platinum sensitive recurrent ovarian cancer patients in August. According to the overseas market data, as the world's first listed PARP inhibitor, olapari accounted for 64% of the global PARP inhibitor market share in 2017, with global sales reaching US $297 million, with a year-on-year growth rate of 36.24%.In 2019, olapali also achieved sales of more than 200 million pocketprep cissp yuan in China's urban retail drugstore terminal, with a year-on-year growth of 952.31%. Considering that the product was approved for the first-line maintenance treatment of BRCA mutation advanced ovarian cancer in December 2019, another indication was expanded in China, and the applicable population was significantly expanded. At present, the drug has also successfully entered the 2019 version of medical insurance catalog, and its sales are expected to continue to maintain an upward trend.

in recent years, pharmaceutical companies have also increased their market share in the retail market. Of course, this is also in line with the cisa exam scoring method fact that the physical retail drugstores actively grasp the varieties of drug companies that flow and discard the standard after purchasing with volume, increase the opportunities of retail layout, speed up the layout of hospital side stores, DTP drugstores and pharmaceutical e-commerce, and vigorously improve the capacity of undertaking prescription drugs and pharmaceutical service.